ArticleFrontiers in medicine2025
Efficacy of whole-brain radiotherapy with or without simultaneous integrated boost in non-small cell lung cancer with brain metastases: a retrospective analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whole-brain radiotherapy (WBRT) remains a cornerstone in the management of brain metastases (BMs) from non-small cell lung cancer (NSCLC), and WBRT with simultaneous integrated boost (WBRT-SIB) emerges as a promising strategy that aims to improve local tumor control through dose escalation while maintaining the coverage of subclinical disease offered by WBRT in theory. However, current evidence regarding the efficacy of WBRT-SIB remains inconclusive. This study aimed to compare the intracranial efficacy of WBRT and WBRT-SIB in NSCLC patients with BMs. Methods: Clinical data from 119 patients with NSCLC-BM treated between 2019 and 2025 were retrospectively analyzed. Local progression-free survival (local PFS) was the primary endpoint, while distant PFS and intracranial PFS (iPFS) were secondary endpoints. Propensity score matching (PSM) was performed to balance baseline characteristics. Kaplan-Meier and Cox regression analyses were applied to identify prognostic factors. Results: No significant differences were observed in local PFS, distant PFS, or iPFS between the WBRT and WBRT-SIB groups, both before and after PSM (all Conclusion: WBRT-SIB provided comparable overall intracranial control to conventional WBRT but achieved superior local tumor control in patients with limited brain metastases (< 8 lesions). These findings support WBRT-SIB as a promising option for selected NSCLC-BM patients, warranting validation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.